安徽安科生物工程（集团）股份有限公司（以下简称"公司"）已于2024年3 月28日披露了公司2023年年度报告及其摘要。 证券代码：300009 证券简称：安科生物 公告编号：2024-020 安徽安科生物工程（集团）股份有限公司 关于召开 2023 年度业绩网上说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特此公告。 为便于广大投资者进一步了解公司2023年度经营情况，公司将于2024年4月 11日（星期四）下午15:00至17:00在"约调研"小程序举行2023年度业绩网上说 明会。本次业绩说明会将采用网络远程的方式举行，投资者可登陆"约调研"小 程序参与互动交流。为广泛听取投资者的意见和建议，现就公司2023年度业绩说 明会提前向投资者征集问题，提问通道自本公告披露之日起开放。 安徽安科生物工程（集团）股份有限公司 董事会 参与方式一：在微信小程序中搜索"约调研"； 出席本次业绩说明会的人员有：公司董事长、总裁宋礼华先生，独立董事刘 光福先生，执行总裁姚建平先生，董事、董事会秘书李坤先生，副总裁窦颖辉先 生，副总裁陆春燕女士，副总裁鲍学科先生 ...

Financial Performance - The company's operating revenue for 2023 reached ¥2,865,752,059.95, representing a 22.94% increase compared to ¥2,331,062,727.29 in 2022[14] - Net profit attributable to shareholders was ¥847,229,426.30, up 20.47% from ¥703,323,479.92 in the previous year[14] - The net profit after deducting non-recurring gains and losses was ¥809,324,373.22, reflecting a 26.07% increase from ¥642,026,644.47 in 2022[14] - The net cash flow from operating activities was ¥952,970,899.58, a 36.34% increase compared to ¥698,977,608.26 in 2022[14] - The total assets at the end of 2023 amounted to ¥4,950,760,486.04, which is a 16.30% increase from ¥4,255,325,817.63 at the end of 2022[14] - The company's net assets attributable to shareholders increased by 16.48% to ¥3,737,399,547.01 from ¥3,208,622,822.65 in 2022[14] - The company reported total operating income of 2.1 billion yuan for the year, with a quarterly breakdown showing a peak of 844.37 million yuan in Q4[43] - The net profit attributable to shareholders for Q4 was 192.81 million yuan, with a total of 210.74 million yuan in Q2 and 258.06 million yuan in Q3[43] - The company has achieved a compound annual growth rate (CAGR) of over 21% in operating revenue and over 23% in net profit attributable to shareholders since its IPO in 2009[61] Business Strategy and Development - The company is focusing on innovative drug development, including ADC drugs and mRNA therapies, to enhance its product pipeline[21] - The company aims to continue its strategic investments in cutting-edge biopharmaceutical technologies and expand its market reach through innovative product offerings[21] - The company is focusing on innovation in new product development and enhancing its core competitiveness to drive high-quality growth[51] - The company is actively exploring project and technology cooperation for external growth while integrating subsidiary resources to support overall performance[54] - The company is responding to national policies by implementing a "going out" strategy to enhance its international presence in the biopharmaceutical sector[49] - The company plans to enhance the utilization rate and economic benefits of the HER2 monoclonal antibody project through market promotion and sales efforts[58] - The company is committed to improving its governance structure and internal management systems to enhance decision-making and protect the rights of minority investors[78] - The company aims to create a diversified collaborative development model centered on its main business while strengthening internal management systems[57] - The company plans to adjust its business structure by deregistering wholly-owned subsidiaries, including Hefei Yuga Information Technology Co., Ltd. and Nanjing Dikon Jinnuo Medical Testing Co., Ltd.[89] Research and Development - The company is advancing the clinical trials for its recombinant human growth hormone-FC fusion protein injection and other new indications, as well as new specifications for its products[74] - The company is accelerating the clinical progress of innovative drugs such as HuA21 injection and expanding its product pipeline in the oncology treatment field[75] - The company completed the third phase of clinical trials for its anti-VEGF monoclonal antibody, aiming for market launch, which is expected to enhance its oncology product line[109] - The total R&D investment amounted to ¥257,743,838.56 in 2023, representing 8.99% of operating revenue, compared to 8.43% in 2022[109] - The number of R&D personnel increased to 479 in 2023, a growth of 1.91% from 470 in 2022, with a higher proportion holding master's degrees[109] - The company adheres to a research and development strategy of "producing one generation, developing one generation, pre-researching one generation, and reserving one generation" to enhance its independent R&D capabilities while collaborating with top domestic research institutions and innovative pharmaceutical companies[200] - The R&D model combines independent innovation with industry-academia-research cooperation and new product introduction[200] Market and Sales Performance - Revenue from biological products was ¥2,099,775,209.52, accounting for 73.27% of total revenue, with a year-on-year growth of 34.93%[84] - The gross profit margin for biological products was 85.70%, a decrease of 1.31% from the previous year[84] - Domestic sales in East China (excluding Anhui) amounted to ¥1,062,123,578.67, up 28.75% from ¥824,924,499.70 in 2022[84] - The sales revenue from traditional Chinese medicine decreased by 11.42% to ¥358,249,174.00, with a gross profit margin of 80.61%[84] - The company experienced a 27.28% decline in foreign sales, totaling ¥2,983,075.21[84] - The company established three new subsidiaries in 2023, enhancing its operational capacity and market reach[104] - The company aims to become a leading provider of health products and services, with a vision of achieving "100 billion Anke, 100 years Anke" in its development strategy[95] - The company will continue to optimize and upgrade existing products while expanding its product line in the field of tumor treatment[95] Governance and Investor Relations - The company emphasizes the importance of independent directors in governance, ensuring that their interests, especially those of minority shareholders, are protected[94] - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective communication with investors and enhancing information disclosure quality[63] - The company has implemented strict confidentiality measures regarding insider information, ensuring compliance with relevant regulations[148] - The company is committed to enhancing investor relations management to improve information transparency and protect the rights of all shareholders, especially minority shareholders[147] - The company emphasizes the importance of maintaining effective communication with investors through various channels, including a dedicated investor hotline and official social media accounts[147] - The company has conducted multiple investor communications, including on-site visits and online exchanges, to discuss operational performance and R&D progress[59] Financial Management - The company raised a total of RMB 682,039,998.08 for four fundraising projects, with a net amount of RMB 663,487,998.08 after deducting issuance costs[58] - The company has implemented a cash dividend policy, distributing a total of RMB 1.827 billion in cash dividends over 14 years, which is 1.85 times the actual funds raised during its IPO and refinancing[62] - The company reported a significant increase in financial expenses, which rose by 59.17% to -¥3,809,223.53 in 2023, attributed to increased interest income from deposits[108] - The net cash flow from financing activities was -400,994,096.55, a decrease of 161.83% compared to the previous year[131] - Cash and cash equivalents decreased by 65,402,131.38, representing a decline of 3,359.85% year-over-year[131] Risks and Challenges - The company faces risks related to new drug development not meeting expectations, which could impact profitability and growth potential[79] - The company is also addressing risks from industry policy changes and centralized procurement that may lead to price reductions for its products[80]

Investment Rating - The report maintains a "Buy" rating for the company [9][28]. Core Views - The company achieved a revenue of 2.866 billion RMB in 2023, representing a year-on-year growth of 23%. The net profit attributable to the parent company was 847 million RMB, up 20% year-on-year [29]. - The growth in revenue is primarily driven by the rapid increase in sales of growth hormone products, which saw a year-on-year increase of 36.24% [29]. - The company is actively investing in research and development, with R&D expenses increasing by 53.41% to 255 million RMB in 2023, supporting the development of new products and enhancing existing ones [29]. Summary by Sections Financial Performance - The company is projected to achieve net profits of 1.073 billion RMB (+27%), 1.351 billion RMB (+26%), and 1.699 billion RMB (+26%) for the years 2024 to 2026, respectively [9]. - The earnings per share (EPS) for 2024, 2025, and 2026 are expected to be 0.64 RMB, 0.81 RMB, and 1.01 RMB, corresponding to price-to-earnings (P/E) ratios of 15, 12, and 9 times [9]. Revenue and Profit Growth - The company’s revenue is expected to grow from 2.331 billion RMB in 2022 to 3.610 billion RMB in 2024, reflecting a growth rate of 25.99% [13]. - The net profit attributable to the parent company is projected to increase from 703 million RMB in 2022 to 1.073 billion RMB in 2024, with a growth rate of 26.66% [13]. R&D and Product Development - The company is focusing on the development of targeted anti-tumor drugs and has made significant progress in clinical trials for several products, including "AK2017 injection" and "AK1012 inhalation solution" [29]. - The product pipeline is expected to continue expanding, providing a solid foundation for long-term growth [29].

证券代码：300009 证券简称：安科生物 公告编号：2024-012 安徽安科生物工程（集团）股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于 2024 年 3 月 26 日召开的第八届董事会第十次会议审议通过了《关于使用闲置自有资金进 行现金管理的议案》，同意公司在确保资金安全、操作合法合规、保证正常生产 经营不受影响的前提下，使用不超过 18 亿元人民币的闲置自有资金通过金融机 构进行现金管理，在确保安全性、流动性的基础上实现资金的保值增值。在上述 额度内，资金可以滚动使用，使用期限为自本次股东大会审议通过之日起 14 个 月内有效，单个理财产品的投资期限不超过 12 个月，并授权公司董事长在上述 额度内行使决策权。 为提高资金使用效率，合理利用闲置自有资金，在不影响公司正常经营的情 况下，利用暂时闲置的自有资金进行现金管理，增加资金效益，更好地实现公司 资金的保值增值，保障公司股东的利益。 一、现金管理情况概述 1、现金管理的目的 2、资金来源及 ...

安徽安科生物工程（集团）股份有限公司 安徽安科生物工程（集团）股份有限公司 董事会议事规则 第一章 总 则 1.宗旨 为了进一步规范安徽安科生物工程（集团）股份有限公司（以下简称"公司"） 董事会的议事方式和决策程序，促使董事和董事会有效地履行其职责，提高董事 会规范运作和科学决策水平，根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司独立董事管理办法》、《深圳证券交易所创业板股票上 市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》）以及《安徽安科生物工程（集团）股份有限公司章程》(以下简称 《公司章程》)等有关规定，制订本规则。 2.董事会职能 董事会是公司经营决策的常设机构，董事会对股东大会负责。董事会应认真 履行有关法律、行政法规和公司章程规定的职责，确保公司遵守法律、行政法规 和公司章程的规定，公平对待所有股东，并关注其他利益相关者的合法权益。 第二章 董事 3.董事应具备以下任职资格： 3.1 公司董事为自然人。 3.2 具有公司运作的基本知识，熟悉国家的经济政策以及有关法律、法规， 具有与担任董事相适应的能力和经验。 3.3 有下列情形之一的 ...

根据财政部、中国证监会等五部门联合发布的《企业内部控制基本规范》、 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等法律法规的要求，安徽安科生物工程（集团）股份有限公司（以下简称"公司"） 监事会对《公司 2023 年度内部控制自我评价报告》发表如下意见： 安徽安科生物工程（集团）股份有限公司监事会 关于 2023 年度内部控制自我评价报告的核查意见 监事会对董事会关于公司 2023 年度内部控制的自我评价报告、公司内部控 制制度的建设和运行情况进行了审核，认为：公司已经建立了较为完善的内部控 制制度，符合国家相关法律法规要求以及公司生产经营管理实际需要，并能够得 到有效的执行；公司内部控制体系的建立和有效执行对公司经营管理的各个环节 起到了较好的风险防范和控制作用，保护了公司的资产安全完整，维护了公司及 股东的利益。公司内部控制的自我评价报告真实、客观地反映了公司内部控制制 度的建设和运行情况。 安徽安科生物工程（集团）股份有限公司 监事会 2024 年 3 月 27 日 ...

审计报告 安徽安科生物工程（集团）股份有限公司 容诚审字[2024]230Z0957 号 容诚会计师事务所(特殊普通合伙) 中国·北京 目录 | 序号 | 内容 | 页码 | | --- | --- | --- | | 1 | 审计报告 | 1-7 | | 2 | 合并资产负债表 | 8 | | 3 | 合并利润表 | 9 | | 4 | 合并现金流量表 | 10 | | 5 | 合并所有者权益变动表 | 11-12 | | 6 | 母公司资产负债表 | 13 | | 7 | 母公司利润表 | 14 | | 8 | 母公司现金流量表 | 15 | | 9 | 母公司所有者权益变动表 | 16-17 | | 10 | 财务报表附注 | 18-143 | 审 计 报 告 容诚会计师事务所(特殊普通合伙) 总所：北京市西城区阜成门外大街 22号 外经贸大厦 15 层/922-926(100037) TEL: 010-6600 1391 FAX: 010-6600 1392 E-mail:bj@rsmchina.com.cn https//WWW.rsm.global/china/ 容诚审字[2024]230Z095 ...

容诚会计师事务所(特殊普通合伙) 中国·北京 目 录 | 序号 | 内 | 容 | 页码 | | --- | --- | --- | --- | | 1 | 内部控制鉴证报告 | | 1-2 | | 2 | 内部控制自我评价报告 | | 3-10 | 容诚会计师事务所(特殊普通合伙) 总所：北京市西城区阜成门外大街 22 号 外经贸大厦 15 层/922-926(100037) TEL: 010-6600 1391 FAX: 010-6600 1392 E-mail:bj@rsmchina.com.cn https//WWW.rsm.global/china/ 内部控制鉴证报告 安徽安科生物工程（集团）股份有限公司 容诚专字[2024]230Z0949 号 安徽安科生物工程（集团）股份有限公司全体股东： 我们鉴证了后附的安徽安科生物工程（集团）股份有限公司（以下简称"安 科生物"）董事会编制的 2023 年 12 月 31 日与财务报告相关的内部控制有效性 的评价报告。 一、对报告使用者和使用目的的限定 本鉴证报告仅供安科生物年度报告披露之目的使用，不得用作任何其他目的。 我们同意将本鉴证报告作为安科生物年度 ...

证券代码：300009 证券简称：安科生物 公告编号：2024-010 安徽安科生物工程（集团）股份有限公司 关于第八届监事会第九次会议决议的公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（下称"公司"）第八届监事会第 九次会议于 2024 年 3 月 16 日以书面形式发出会议通知，2024 年 3 月 26 日下午 5:00 在公司 1002 会议室召开。应参会监事 3 人，实际参会监事 3 人。本次会议 的召开与表决程序符合《公司法》和《公司章程》等的有关规定，会议由监事李 增礼先生主持。 经与会监事充分讨论，表决通过如下决议： 一、以 3 票赞成，0 票反对，0 票弃权审议通过了《公司 2023 年度监事会 工作报告》 本议案尚需提交 2023 年度股东大会审议。 二、以 3 票赞成，0 票反对，0 票弃权审议通过了《公司 2023 年度财务决 算报告》 依据相关规定和要求，公司已根据 2023 年度的经营情况、资产情况编写了 公司 2023 年度财务决算报告。 本议案尚需提交公司 2023 年度股东大会审议。 ...

具体修订对照如下： | 原条款 | 修订后条款 | | --- | --- | | 第六条 公 司 注 册资 本 为 人 民 币 | 第 六 条 公司注册资本为人民币 | | 【1,673,257,958】元。 | 【1,676,346,758】元。 | | 第十一条 本章程所称其他高级管理 | 第十一条 本章程所称其他高级管理人员是 | | 人员是指公司的高级副总裁、副总裁、董 | 指公司的执行总裁、高级副总裁、副总裁、董事 | | 事会秘书、财务负责人、资本运营总监。 | 会秘书、财务负责人及公司董事会聘任的其他高 | | | 级管理人员。 | | 第十四条 经依法登记，公司的经营范 | 第十四条 经依法登记，公司的经营范围： | | 围：一般项目：医学研究和试验发展；专 | 一般项目：医学研究和试验发展；专用化学产品 | | 用化学产品制造（不含危险化学品）；专用 | 制造（不含危险化学品）；专用化学产品销售（不 | | 化学产品销售（不含危险化学品）；技术服 | 含危险化学品）；技术服务、技术开发、技术咨 | | 务、技术开发、技术咨询、技术交流、技 | 询、技术交流、技术转让、技术推广；细胞技术 | ...